Therapy (HCV)

Interferon Therapy Not Well Tolerated By Hemodialysis Patients

Published in Blood Weekly, May 17th, 2001

by Sonia Nichols, senior medical writer - Interferon alpha therapy, used alone or in combination with other drugs, is a core treatment for hepatitis C virus (HCV) patients. However, a study from France reports interferon is poorly tolerated in HCV patients on hemodialysis.

Even so, according to Francoise Degos and coauthors of the multicenter, collaborative study, HCV patients on hemodialysis who can complete 12 months of treatment may benefit from interferon therapy.

Initially, researchers planned to enroll into the study 120 hemodialysis patients with confirmed evidence of viral infection. "After 37 patients had been included, the study was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry